ERBB2 and breast carcinoma: Since the new substance trastuzumab deruxtecan was shown to be effective in breast cancer tumors with “low” HER2 expression [23], more attention has been paid to breast cancer cases with a 1+ or 2+ immunohistochemical (IHC)-HER2 expression [24].